·
Wake
·
cart
flowcytometry
ai
qualitycontrol
immunotherapy
The CAR-T Manufacturing Bottleneck: Why $500K Still Can't Guarantee a Cure
33% of lymphoma patients never receive their CAR-T infusion because manufacturing fails first. The root cause: a 4-marker QC system in a 36-marker world. Here's what I found when I went looking for answers — and why AI-driven spectral flow cytometry might be the solution.
